Vertical Integration CDMO Capabilities

The rapidly growing demand for nucleic acid therapeutics (NATs) is reflected in the global CDMO market (USD 20.3B in 2023, projected USD 33.86B by 2030). Traditional fragmented supply chains increase misalignment and delays. Hongene’s vertically integrated model consolidates high‑quality raw materials, cGMP production, and fill‑finish into a single end‑to‑end supply chain, accommodating all NAT modalities (siRNA, ASOs, mRNA). This reduces risk, improves continuity, and supports large‑volume API demand for large patient populations. Hongene accelerates time‑to‑market while ensuring regulatory compliance.

(To explore cost‑benefit analyses, capacity expansion case studies, and regulatory compliance details under our vertical integration model, please download the full industry whitepaper.)